Abstract
Commentary on the latest phase 2 results of crizanlizumab, a novel pharmaceutical agent for the prevention of vaso-occlusive crises in patients suffering from sickle cell disease.
Original language | American English |
---|---|
Journal | Practical Pain Management |
DOIs | |
State | Published - Dec 2016 |
Disciplines
- Hematology